MORGAN STANLEY PLC/CALL/MODERNA/107.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 15:51:03 2024-07-05 EDT | ||
| 2.42 EUR | +0.41% |
|
| 3 months | +39.08% | ||
| 6 months | -8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 2.42 | +0.41% |
| 24-07-04 | 2.41 | +6.64% |
| 24-07-03 | 2.26 | -3.42% |
| 24-07-02 | 2.34 | +1.74% |
| 24-07-01 | 2.3 | -4.96% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 03:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB8JCQ |
| ISIN | DE000MB8JCQ8 |
| Date issued | 2023-07-10 |
| Strike | 107.5 $ |
| Maturity | 2024-12-20 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 3.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.41 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.05 € |
| Spread % | 2.02% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Warrants
- Warrant
